Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,500
Employees2,500
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,500
Employees2,500

ALNY Key Statistics

Market cap
38.96B
Market cap38.96B
Price-Earnings ratio
69.39
Price-Earnings ratio69.39
Dividend yield
Dividend yield
Average volume
1.19M
Average volume1.19M
High today
$298.38
High today$298.38
Low today
$288.56
Low today$288.56
Open price
$290.61
Open price$290.61
Volume
949.67K
Volume949.67K
52 Week high
$495.55
52 Week high$495.55
52 Week low
$261.85
52 Week low$261.85

Stock Snapshot

Alnylam Pharmaceuticals(ALNY) stock is priced at $291.48, giving the company a market capitalization of 38.96B. It carries a P/E multiple of 69.39.

During the trading session on 2026-05-13, Alnylam Pharmaceuticals(ALNY) shares reached a daily high of $298.38 and a low of $288.56. At a current price of $291.48, the stock is +1.0% higher than the low and still -2.3% under the high.

Trading activity shows a volume of 949.67K, compared to an average daily volume of 1.19M.

The stock's 52-week range extends from a low of $261.85 to a high of $495.55.

The stock's 52-week range extends from a low of $261.85 to a high of $495.55.

ALNY News

Simply Wall St 5d
Is It Time To Reconsider Alnylam Pharmaceuticals After Recent RNAi Progress And Volatile Price Moves

Wondering whether Alnylam Pharmaceuticals at around US$295.91 is offering fair value right now, or if the price is running ahead of the story? This article brea...

Is It Time To Reconsider Alnylam Pharmaceuticals After Recent RNAi Progress And Volatile Price Moves

Analyst ratings

69%

of 29 ratings
Buy
69%
Hold
31%
Sell
0%

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.